We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline execs touted their HIV growth drive this week, pointing to next-generation medications Triumeq and Tivicay as the fuel.But both drugs actually fell short of analyst forecasts...